Innovationsmanager in kleinen und mittleren Unternehmen (KMU) der Pharmaindustrie bei der Einführung des Open Innovation Managements zu …Vorliegender Leitfaden ist eines der Ergebnisse des Forschungsprojekts „Open Innovation in Life Sciences“ (OIL), das … unterstützen.Zielsetzung des Forschungsprojekts war es, (1) die Chancen und Risiken von Open Innovation unter besonderer …

on changes in technology, marketing, and financing practices. An examination of the changes in technology is undertaken … differentiating between an expense and a knowledge based escalation strategy. The chapter on marketing emphasizes innovative and non … results of the examination of the technology, marketing and financing practices, it further confronts the decisive factors …

Full-text of this article is not available in this e-prints service. This article was originally published in Marketing …. Legal restrictions on manipulating the conventional marketing mix are discussed and alternative strategic moves towards …

Evaluation nutzt dabei zuerst Daten des Mannheimer Innovation Panel für die Untersuchung in Deutschland und später Daten der … Community Innovation Survey für die Untersuchung in Europa. Die Ergebnisse zeigen, dass die drei verschiedenen Ebenen der …

those applied in the sales and distribution points ofthe pharmaceutical products. Some ways of enhancing marketing among the …

inform marketing managers on their choices in strategy. Findings suggest that research in this arena is in its infancy and …

, various aspects of the innovation behaviour of the companies are highlighted. It is shown that funding from earned profits has … highlighted for medium-sized project?s in the field of innovation financing. …

innovation process through the distribution and marketing of pharmaceuticals. In contrast to other products, drugs can be … innovation, and delays in new drug therapies available to consumers.2 Government laws and regulations indirectly affect the …

findings have implications for the future of vaccine development, as well as for the analysis of biomedical innovation in our …